Updates in chronic graft-versus-host disease management.
Malard F, Mohty M.
Am J Hematol. 2023 Oct;98(10):1637-1644. doi: 10.1002/ajh.27040. Epub 2023 Jul 22.
Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.
Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW.
J Am Acad Dermatol. 2024 Jan;90(1):1-16. doi: 10.1016/j.jaad.2022.12.024. Epub 2022 Dec 23.
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults.
Bos S, Murray J, Marchetti M, Cheng GS, Bergeron A, Wolff D, Sander C, Sharma A, Badawy SM, Peric Z, Piekarska A, Pidala J, Raj K, Penack O, Kulkarni S, Beestrum M, Linke A, Rutter M, Coleman C, Tonia T, Schoemans H, Stolz D, Vos R.
Eur Respir J. 2024 Mar 28;63(3):2301727. doi: 10.1183/13993003.01727-2023. Print 2024 Mar.
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG; BMT CTN 1703 Investigators.
N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943.
Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.
Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW.
J Am Acad Dermatol. 2024 Jan;90(1):19-36. doi: 10.1016/j.jaad.2022.12.023. Epub 2022 Dec 23.
Ocular graft-versus-host disease (oGVHD): From A to Z.
Soleimani M, Mahdavi Sharif P, Cheraqpour K, Koganti R, Masoumi A, Baharnoori SM, Salabati M, Djalilian AR.
Surv Ophthalmol. 2023 Jul-Aug;68(4):697-712. doi: 10.1016/j.survophthal.2023.02.006. Epub 2023 Mar 2.
Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
Zeiser R.
J Clin Oncol. 2023 Apr 1;41(10):1820-1824. doi: 10.1200/JCO.22.02256. Epub 2023 Feb 17.
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
Kitko CL, Arora M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ.
J Clin Oncol. 2023 Apr 1;41(10):1864-1875. doi: 10.1200/JCO.22.00958. Epub 2022 Dec 2.
Chronic graft-versus-host disease in pediatric patients: Differences and challenges.
Haroun E, Agrawal K, Leibovitch J, Kassab J, Zoghbi M, Dutta D, Lim SH.
Blood Rev. 2023 Jul;60:101054. doi: 10.1016/j.blre.2023.101054. Epub 2023 Feb 8.
Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
Baccelli F, Gottardi F, Muratore E, Leardini D, Grasso AG, Gori D, Belotti T, Prete A, Masetti R.
Bone Marrow Transplant. 2024 Jun;59(6):765-776. doi: 10.1038/s41409-024-02252-z. Epub 2024 Feb 24.
